LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/13/2025
Back to search
Official data from USPTO
TIGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TIGEN
ST13
US500000079304640Class
1, 5, 10, 42, 44
Filing
79304640
Registration
6674502
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
06/14/2025
Trademark type
Word
Nice classes
1, 5, 10, 42, 44
Filing date
11/13/2020
Registration date
03/22/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/22/2022
Last transaction
06/14/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
33
Owner location
CH
Examiner
BLAZICH,JOAN MICHELE
Law office
O30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Tigen Pharma SA
Representatives
Stacey Halpern Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 1Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in industry and science; chemicalbiochemicalbiological and biotechnological preparationspolypeptides and proteinsfor use in the development being the manufacturemanufacture of reagents for industrial or scientific use; chemicalbiochemicalbiological and biotechnological preparationspolypeptides or proteinsfor use of laboratoriesdiagnostics and analyses for industrial or scientific use; chemicalbiochemicalbiological and biotechnological substancespolypeptides and proteinsfor use in the manufacture of pharmaceuticals
Class 5
Pharmaceutical products and medical preparationsgene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseasesgenetic diseasesautoimmune diseases and infectious diseases
Class 10
Medical instrumentsequipment and apparatusinstrumentsequipment and apparatus for cell and cell material collectionthawingwashingselectionexpansionmodificationharvestingfinal formulationfreezingstorage and infusion into a patient in the fields of genetic diseasesautoimmune diseasesinfectious diseaseslocalized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions
Class 42
Scientific researchtechnological development of new products for third parties; medical research; scientific and industrial research in biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific servicesdevelopment of medicinesactive substances and vaccines; scientific servicesdevelopment of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; upgradingmaintenance and rental of computer software; updatingmaintenance and rental of computer software for use in medical and scientific research and in the development of new productsin research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process developmentmanufacturingqualitysupply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnologybiologydiseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases and the treatment of diseasesgenetic diseasesautoimmune diseasesinfectious diseases and tumor diseases; chemical and biological laboratory services
Class 44
Medical services; pharmacy advice servicespharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists
Publications
History of USPTO decisions and trademark events.
33 publications found
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/06/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/31/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
09/05/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/15/2022
FIMP
FINAL DISPOSITION PROCESSED
08/15/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/22/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
03/22/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/04/2022
PUBO
PUBLISHED FOR OPPOSITION
01/04/2022
GPNX
NOTIFICATION PROCESSED BY IB
01/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/15/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/15/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/15/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/29/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
11/29/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/29/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
11/29/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/08/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/08/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/27/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/20/2021
RFNT
REFUSAL PROCESSED BY IB
05/31/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/07/2021
RFRR
REFUSAL PROCESSED BY MPU
05/07/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/04/2021
CNRT
NON-FINAL ACTION WRITTEN
05/03/2021
DOCK
ASSIGNED TO EXAMINER
04/24/2021
MAFR
APPLICATION FILING RECEIPT MAILED
02/23/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/19/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/18/2021
Continuous trademark protection
Get notified about every new filing that threatens TIGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.